AI Therapeutics CEO and leadership

Experienced biotech/pharmaceutical executive with extensive strategic and operational experience in multiple disease areas (especially oncology, autoimmune, metabolic, cardiovascular) and drug classes (small molecules, peptides and biologics). Demonstrated track record in drug discovery. Includes all stages from target identification through IND to translation into the clinic. Contributed to the discovery and/or development of Promacta (for ITP), Omontys (for anemia), Imbruvica (for MCL and CLL), Nucala (for severe eosinophilic asthma), apabetalone/RVX-208 (Phase III for atherosclerosis), and multiple Phase I/II compounds.Extensive multi-disciplinary management, project leadership and budgetary oversight of technologies required for drug discovery and non-clinical/clinical development (e.g. gene expression, protein purification, assay development, screening, proteomics, biomarker discovery, cell biology, chemistry, analytical, pharmacology, toxicology, translational medicine). This includes evaluation and management of successful technology and pipeline partnerships, collaborations and CROs, as well as in-licensing opportunities. Prolific and innovative, as demonstrated by a strong record of publication (|120 papers and reviews) and inventorship (34 patents). Adaptability demonstrated by successful work on multiple therapeutic target classes and disease mechanisms.

Scott received a BS in Marketing from the University of Connecticut, School of Business, and earned an MBA in (International) Marketing from Georgia State University’s Kennesaw State University Michael J. Coles School of Business. Scott has over 30 years of experience in the pharmaceutical/life science industry and has held senior positions in marketing, brand management, business development, licensing & corporate development. He has helped companies partner assets, raise funds and go public. Over the past decade, Scott co-founded several companies including New Haven Pharmaceuticals, Prevention Pharmaceuticals and Rho Renewables. As part of his consulting business since 2008 which helps life science companies with fundraising, partnering and general business development he was most recently the Head of Business Development for Universal Sequencing Technology (UST), a next-generation DNA Sequencing company located in Boston. Additionally, he was Head of Licensing & Business Development for AlloMek, a New Haven, CT-based Rare Disease & Oncology company, founded by ex-Bayer scientists & backed by the CT-based venture capital group Connecticut Innovations. Scott has also worked with the UCONN Incubator company, Potentiometric Probes, a company that is marketing Voltage-Sensitive Dyes for cardiovascular & neurological drug discovery, to help them raise funds and find global distribution partners. In 2018, Scott became an Adjunct Professor at the University of Connecticut Graduate School of Business, Connecticut Center for Entrepreneurship & Innovation (CCEI). He is currently teaching Biomedical Entrepreneurship and in the Spring 2020 had oversight for a newly created course, Entrepreneurship Mentoring, an Independent Study opportunity for students trying to determine viability for their products & ideas. He is currently an Entrepreneur in Residence and Professor of Practice at CCEI. Since 2017, Scott has been a mentor to undergraduates in the UCONN School of Business as well as at CCEI, supporting several of their NSF iCorp funded courses and programs.

Joan Edwards is the Head of Quality Assurance for AI Therapeutics. Ms. Edwards has worked as the Head of Quality for the last 10 years in the pharmaceutical industry. Additionally, Ms. Edwards has over 20 years of experience working in Quality in the medical device field. She began her career working for Becton Dickinson. She has developed, implemented, and continuously improved Quality Management Systems resulting in effective quality compliance. She has managed multiple companies and departments in the testing and release of drug and medical device products and the review of documentation for quality compliance with company and regulatory standards. She has audited and hosted inspections for regulatory compliance and due diligence business initiatives.

Keith Fandrick graduated with his Ph.D. in Chemistry from Harvard under the guidance of Professor David Evans where he worked on novel asymmetric methodologies and asymmetric synthesis of complex natural products. After graduation he joined the Chemical Development group at Boehringer Ingelheim where he was charged with the development of safe, economical and robust asymmetric synthesis of challenging compounds. His background and experience also include computational modeling with Quantum Mechanical/Density Function Theory. Dr. Fandrick has over 70 publications and patents, and currently serves as the Head of Chemistry and CMC at AI Therapeutics.